Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Weight Loss Using the Take Shape For Life Program or the Medifast Direct Program Versus a Self-Directed Diet
- Conditions
- ObesityOverweight
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Medifast, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT02835092
- Locations
- 🇺🇸
Biofortis Innovation Services, Addison, Illinois, United States
Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans
- Conditions
- Obesity
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Medifast, Inc.
- Target Recruit Count
- 372
- Registration Number
- NCT02150837
- Locations
- 🇺🇸
Medifast, Inc., Owings Mills, Maryland, United States
A Retrospective Chart Review of Three Medifast Weight Control Centers
- Conditions
- Obesity
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Medifast, Inc.
- Target Recruit Count
- 446
- Registration Number
- NCT01662830
Evaluation of Metabolism-Boosting Beverages
- Conditions
- AppetiteEnergy Expenditure
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- Medifast, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01029236
- Locations
- 🇺🇸
Medifast Inc., Owings Mills, Maryland, United States
SUCCESS Tracking Study
- Conditions
- Obesity
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Medifast, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT01021917
- Locations
- 🇺🇸
Medifast Inc., Owings Mills, Maryland, United States
- Prev
- 1
- 2
- Next
News
Novel Peptide Compounds Show Promise as Ozempic Alternatives with Reduced GI Side Effects
Researchers have developed two new peptide compounds, GEP44 and KCEM1, that target weight loss with potentially fewer gastrointestinal side effects than current GLP-1 drugs.
Weight Loss Market Sees Rapid Growth with New Drugs and Supplements
The weight loss drugs market is predicted to grow rapidly, with analysts at SNS Insider forecasting a 43.73% CAGR through 2032, driven by rising obesity rates.